Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Scott Olson/Getty Images
A new initiative — funded by DARPA, the Pentagon's high-tech research arm — is aiming to make it much easier to scale up the next generation of RNA- and DNA-based vaccines.
Driving the news: A consortium including GE Research, the Broad Institute and the University of Washington is announcing today that it's secured a $41 million grant from DARPA.
- The researchers will use that money to develop a new platform that, they say, would enable an automated and mobile manufacturing process.
- Ultimately, the hope is that this platform could be distributed nationwide to quickly scale up manufacturing and cut down on distribution time.
Why it matters: We're dealing now with the first-ever mRNA vaccines — technology that has the potential to produce more effective inoculations for a range of viruses. And even as those vaccines are still rolling out, scientists are already at work on ways to make the next versions of these products even more efficient.
- "Having the ability to produce small batches of ready-to-use vaccines in under three days at the site of need would enable widespread deployment of doses at an unprecedented speed," John Nelson, the leader of the GE Research team, said in a statement.